Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes

Abstract

This study compared the long-term effects of pioglitazone and gliclazide on the production of coagulation factors in patients with type 2 diabetes. Patients (n=283) with glycosylated haemoglobin > 7.5% were randomised to receive either pioglitazone (30–45 mg/day) or gliclazide (80–320 mg/day) for one year. Coagulation factors were measured at baseline and at six and 12 months. While both pioglitazone and gliclazide induced a comparable improvement in glycaemic control, only pioglitazone improved insulin sensitivity. Pioglitazone significantly (p<0.001) decreased circulating levels of von Willebrand factor (-9.7%, −9.4%) and plasminogen activator inhibitor-1 (-16.8 ng/ml, −12.3 ng/ml), and increased levels of antithrombin-III (+1.3 mg/dL, +1.5 mg/dL) after six and 12 months, respectively. The beneficial effects of pioglitazone on glycaemic control, lipid homeostasis, and coagulation and thrombosis, may improve vascular outcomes in patients with type 2 diabetes.

Keywords

cardiovascular disease coagulation diabetes gliclazide pioglitazone thrombosis

References

1. Schnell O , Standl E. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract 2006;12(suppl 1):16–19.

2. Thorand B , Baumert J , Chambless L. et al. Elevated markers of endothe-lial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006;26:398–405.

3. Colwell JA , Nesto RW. The platelet in diabetes. Focus on prevention of ischemic events. Diabetes Care 2003;26:2181–8.

4. Candido R , Zanetti M. Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis. Ital Heart J 2005;6:703–20.

5. Schneider DJ. Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis 2005;16:473–6.

6. Jokl R , Colwell JA. Arterial thrombosis and atherosclerosis in diabetes. Diabetes Metab Rev 1997;5:1–15.

7. Jokl R , Colwell JA. Clotting disorders in diabetes. In: Alberti KGMM , Zimmet P , Defronzo R , Koen H , ed. International Textbook of Diabetes Mellitus. 2nd edition. Chichester: Wiley, 1997:1543–57.

8. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006;95:49–55.

9. Juhan-Vague I , Alessi MC , Mavri A. et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance, and vascular risk. J Thromb Haemost 2003;1:1575–9.

10.

10. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005;3:1879–83.

11.

11. Vaidyula VR , Rao AK , Mozzoli M. et al. Effects of hyperglycaemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006;55:202–08.

12.

12. Stegenga ME , van der Crabben SN , Levi M. et al. Hyperglycemia stimulated coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006;55:1807–12.

13.

13. Verges B. Clinical interest of PPARs ligands. Particular benefit in type 2 diabetes and metabolic syndrome. Diabetes Metab 2004;30:7–12.

14.

14. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29:S44–52.

15.

15. Chu JW , Abbasi F , Lamendola C. et al. Effect of rosigl itazone on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vasc Dis Res 2005;2:37–41.

16.

16. Kruszynska YT , Yu JG , Olefsky JM. et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49:633–9.

17.

17. Derosa G , Cicero AF , Gaddi A. et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005;69:5–13.

18.

18. De Jager J , Kooy A , Lehert P. et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005;257:100–09.

19.

19. Fonseca V , Theuma P , Mudaliar S. et al. Diabetes treatments have differential effects on non-traditional cardiovascular risk factors. J Diabetes Complications 2006;20:14–20.

20.

20. Perriello G , Pampanelli S , Di Pietro C et al. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabet Med 2006;23:246–52.

21.

21. Chandler WL , Alessi MC , Aillaud MF. et al. Formation, inhibition and clearance of plasmin in vivo. Haemostasis 2000;30:204–18.

22.

22. Spiess B , Chandler WL. Genetic basis of procoagulant and fibrinolytic perioperative adverse events. Best Practice & Research Clinical Anaesthesiology 2001;15:195–211.

23.

23. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006;4:1186–93.

24.

24. Cefalu WT , Schneider DJ , Carlson HE. et al. Effect of combination glipazide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care 2002;25:2123–8.

25.

25. Gin H , Roudaut MF , Vergnot V. et al. Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients. Diabetes Metab 2003;29:505–08.

26.

26. Grant PJ , Stickland MH , Booth NA. et al. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991;8:361–5.

27.

27. Charles MA , Morange P , Eschwege E. et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese non-diabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998;21:1967–72.

28.

28. Caballero AE , Delgado A , Aguilar-Salinas CA et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled randomized clinical trial. J Clin Endocrinol Metab 2004;89:3943–8.

29.

29. Liu HB , Hu YS , Medcalf RL. et al. Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 2005;334:30–7.

30.

30. Pfutzner A , Marx N , Lubben G. et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925–31.

31.

31. Yamaguchi M , Nishimura F , Naruishi H. et al. Thiazolidinedione (pioglitazone) blocks P. gingivalis and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes. J Dent Res 2005;84:240–4.

32.

32. Blann AD , Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 2003;14:335–40.